Loading…
Legislative Progress
Introduced
December 17, 2019
Latest Action
December 17, 2019
Primary Sponsor
Shelley Moore CapitoRepublican(WV)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Non-Opioids Prevent Addiction In the Nation Act or the NOPAIN Act This bill temporarily establishes separate payments for certain non-opioid treatments under the Medicare prospective payment system for hospital outpatient department services and the payment system for ambulatory surgical center services. The bill applies to pain management treatments that are able to replace or reduce opioid consumption, as shown through clinical trials or data.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (12)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Medicare/Medicaid
H.R. 8840, Medicare Sequester COVID Moratorium Act, all provisions H.R. 8702, Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020, all provisions S. 5007, Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020, all provisions H.R. 7154, Outpatient Therapy Modernization and Stabilization Act, all provisions H.R. 3107, Improving Seniors Timely Access to Care Act of 2019, all provisions S. 5044, Improving Seniors Timely Access to Care Act of 2020y, all provisions H.R. 8727, Telehealth Modernization Act, all provisions S. 4375, Telehealth Modernization Act, all provisions H.R. 7663, Protecting Access to Post-COVID-19 Telehealth Act of 2020, all provisions H.R. 7391, Protect Telehealth Access Act of 2020, all provisions H.R. 1301, Mental Health Telemedicine Expansion Act, all provisions H.R. 3417, Beneficiary Education Tools, Telehealth, and Extenders Reauthorization (BETTER) Act of 2019, all provisions H.R. 5201, Telemental Health Expansion Act of 2020, provisions relating to 1834(m) of the Social Security Act; geographic and originating sites H.R. 7233, Knowing the Efficiency and Efficacy of Permanent (KEEP) Telehealth Options Act of 2020, all provisions H.R. 5172, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, All provisions S. 3067, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, All provisions H.R. 3414, Opioid Workforce Act of 2019, all provisions H.R. 7791, Value in Health Care Act of 2020, provisions relating to qualifying APM physician thresholds H.R. 6837, Medicare Accelerated and Advance Payments Improvement Act of 2020, all provisions S. 3750, Medicare Accelerated and Advance Payments Improvement Act, all provisions H.R. 8505, To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes, all provisions H.R. 884, Medicare Mental Health Access Act, all provisions H.R. 945, Mental Health Access Improvement Act of 2019, all provisions H.R. 6744, Medically Tailored Home-Delivered Meals Demonstration Pilot Act of 2020, all provisions H.R. 4004, Social Determinants Accelerator Act of 2019, all provisions H.R. 4932, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019, all provisions S. 2741, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019, all provisions H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, all provisions S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, all provisions H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to PBM and prescription drug price transparency H.R. 19, Lower Costs, More Cures Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 4996, Helping Medicaid Offer Maternity Services (MOMS) Act of 2020, all provisions H.R. 6090, Physician Shortage GME Cap Flex Act of 2020, all provisions H.R. 6142, Black Maternal Health Momnibus Act of 2020, all provisions Medicare program: P.L. 114-10 Medicare Access and CHIP Reauthorization Act (MACRA) implementation/Accountable Care Organizations/APM thresholds Medicare program: Patient Protection and Affordable Care Act (PPACA)/Prior authorization provider and patient burdens/patient electronic access to health information Medicare program: P.L. 113-93 Protecting Access to Medicare Act (PAMA)/Imaging appropriate use criteria/Radiation Oncology APM Medicare program: FY 2021 Inpatient Rehab Facility Prospective Payment System (IRF PPS)/scope of practice issues Medicare program: CY 2021 physician fee schedule/E&M services/Budget neutrality/Part B/Sequester Medicare program: Alternative payment models (APMs) Medicare program: Merit-based Incentive Payment System (MIPS)/cost/quality/interoperability/hardship exemption Medicare program: Regulatory relief/Advanced APMs, prior authorization, and utilization management Medicare program: Shared Savings Program Medicare program: Quality Payment Program/prior authorization/electronic funds transfer Medicare program: Surprise medical billing Medicare program: Medicare-For-All Medicare program: Electronic Health Records (EHR) Certification Medicare program: 21st Century Cures Act Medicare program: Quality payment program/physician burdens Medicare program: National Coverage determination/validated home blood pressure monitors Medicare program: Health IT/physician burden Medicare program: Drug pricing Medicare program: Most favored nation drug pricing Medicare program: Provider compliance/regulatory relief Medicare program: Provider Enrollment, Chain and Ownership (PECOS) enrollment/revalidation Medicare and Medicaid programs: 21st Century Cures Act/health data and privacy Medicaid program: CMS proposed regulation Medicaid Program Medicaid program: FMAP increases Medicaid program: Interoperability
Client expense: $3,870,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. H.R. 5172, NOPAIN Act, all provisions. S. 3067, Non-Opioids Prevent Addiction In the Nation Act, all provisions. H.R. 133, Consolidated Appropriations Act, 2021, provisions relating to coronavirus stimulus and recovery.
Client expense: Not reported · Firm income: $22,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; H.R. 5172, NOPAIN Act; S. 3067, Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · fourth_quarter · Health Issues
S. 3067, Non-Opioids Prevent Addiction In the Nation Act; H.R. 5172, NOPAIN Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · fourth_quarter · Medicare/Medicaid
Monitored issues related to prescription drug prices; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives; issues related to the 2021 OPPS final rule; monitored issues related to H.R. 133, the Consolidated Appropriations Act of 2021.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
| Democratic |
| MI |
| Jacky Rosen | Democratic | NV |
| James Lankford | Republican | OK |
| James M. Inhofe | Republican | OK |
| Jeanne Shaheen | Democratic | NH |
| Joe Manchin, III | Independent | WV |
| John Barrasso | Republican | WY |
| John Boozman | Republican | AR |
| Jon Tester | Democratic | MT |
| Joni Ernst | Republican | IA |
| Kevin Cramer | Republican | ND |
| Kyrsten Sinema | Independent | AZ |
| Marsha Blackburn | Republican | TN |
| Martha McSally | Republican | AZ |
| Pat Roberts | Republican | KS |
| Rob Portman | Republican | OH |
| Steve Daines | Republican | MT |
| Susan M. Collins | Republican | ME |
| Tammy Baldwin | Democratic | WI |
| Thom Tillis | Republican | NC |
| Tim Scott | Republican | SC |
2020 · fourth_quarter · Medicare/Medicaid
H.R. 8840, Medicare Sequester COVID Moratorium Act, all provisions H.R. 8702, Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020, all provisions S. 5007, Holding Providers Harmless From Medicare Cuts During COVID-19 Act of 2020, all provisions H.R. 7154, Outpatient Therapy Modernization and Stabilization Act, all provisions H.R. 3107, Improving Seniors Timely Access to Care Act of 2019, all provisions S. 5044, Improving Seniors Timely Access to Care Act of 2020y, all provisions H.R. 8727, Telehealth Modernization Act, all provisions S. 4375, Telehealth Modernization Act, all provisions H.R. 7663, Protecting Access to Post-COVID-19 Telehealth Act of 2020, all provisions H.R. 7391, Protect Telehealth Access Act of 2020, all provisions H.R. 1301, Mental Health Telemedicine Expansion Act, all provisions H.R. 3417, Beneficiary Education Tools, Telehealth, and Extenders Reauthorization (BETTER) Act of 2019, all provisions H.R. 5201, Telemental Health Expansion Act of 2020, provisions relating to 1834(m) of the Social Security Act; geographic and originating sites H.R. 7233, Knowing the Efficiency and Efficacy of Permanent (KEEP) Telehealth Options Act of 2020, all provisions H.R. 5172, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, All provisions S. 3067, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, All provisions H.R. 3414, Opioid Workforce Act of 2019, all provisions H.R. 7791, Value in Health Care Act of 2020, provisions relating to qualifying APM physician thresholds H.R. 6837, Medicare Accelerated and Advance Payments Improvement Act of 2020, all provisions S. 3750, Medicare Accelerated and Advance Payments Improvement Act, all provisions H.R. 8505, To amend title XVIII of the Social Security Act to provide for a one-year waiver of budget neutrality adjustments under the Medicare physician fee schedule, and for other purposes, all provisions H.R. 884, Medicare Mental Health Access Act, all provisions H.R. 945, Mental Health Access Improvement Act of 2019, all provisions H.R. 6744, Medically Tailored Home-Delivered Meals Demonstration Pilot Act of 2020, all provisions H.R. 4004, Social Determinants Accelerator Act of 2019, all provisions H.R. 4932, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019, all provisions S. 2741, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019, all provisions H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, all provisions S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, all provisions H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to PBM and prescription drug price transparency H.R. 19, Lower Costs, More Cures Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 4996, Helping Medicaid Offer Maternity Services (MOMS) Act of 2020, all provisions H.R. 6090, Physician Shortage GME Cap Flex Act of 2020, all provisions H.R. 6142, Black Maternal Health Momnibus Act of 2020, all provisions Medicare program: P.L. 114-10 Medicare Access and CHIP Reauthorization Act (MACRA) implementation/Accountable Care Organizations/APM thresholds Medicare program: Patient Protection and Affordable Care Act (PPACA)/Prior authorization provider and patient burdens/patient electronic access to health information Medicare program: P.L. 113-93 Protecting Access to Medicare Act (PAMA)/Imaging appropriate use criteria/Radiation Oncology APM Medicare program: FY 2021 Inpatient Rehab Facility Prospective Payment System (IRF PPS)/scope of practice issues Medicare program: CY 2021 physician fee schedule/E&M services/Budget neutrality/Part B/Sequester Medicare program: Alternative payment models (APMs) Medicare program: Merit-based Incentive Payment System (MIPS)/cost/quality/interoperability/hardship exemption Medicare program: Regulatory relief/Advanced APMs, prior authorization, and utilization management Medicare program: Shared Savings Program Medicare program: Quality Payment Program/prior authorization/electronic funds transfer Medicare program: Surprise medical billing Medicare program: Medicare-For-All Medicare program: Electronic Health Records (EHR) Certification Medicare program: 21st Century Cures Act Medicare program: Quality payment program/physician burdens Medicare program: National Coverage determination/validated home blood pressure monitors Medicare program: Health IT/physician burden Medicare program: Drug pricing Medicare program: Most favored nation drug pricing Medicare program: Provider compliance/regulatory relief Medicare program: Provider Enrollment, Chain and Ownership (PECOS) enrollment/revalidation Medicare and Medicaid programs: 21st Century Cures Act/health data and privacy Medicaid program: CMS proposed regulation Medicaid Program Medicaid program: FMAP increases Medicaid program: Interoperability
Client expense: $4,170,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, medical device technology related to the opioid epidemic and the COVID-19 pandemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Client expense: $250,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Navy, Dept of, SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Medical device technology related to the opioid epidemic and the COVID-19 pandemic. H.R.5172/S.3067, NOPAIN Act.
Client expense: Not reported · Firm income: $40,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Increase access to acupuncture as an alternative pain-management option to opioids. H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Increase access to acupuncture as an alternative pain-management option to help combat opioid abuse. H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for certified acupuncturists H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
S. 1895: Lower Health Care Costs Act S.523, H.R. 1243: Climate Change and Health Promotion Act S. 1737, H.R. 3165: Mental Health Parity Compliance Act H.R. 2848: Parity Enforcement Act H.R. 3495: Improve Well-Being for Veterans Act H.R. 1884: Protecting Pre-Existing Conditions and Making Health Care More Affordable Act of 2019 S. 4761: H.R. 5574 Primary and Behavioral Health Care Access Act H.R. 5172, S. 3067: Non-Opioids Prevent Addiction in the Nation Act H.R. 5469: Pursuing Equity in Mental Health Act of 2019 LR H.R. 1016, S. 2741: CONNECT for Health Act H.R. 4543: Reducing Mental Health Stigma in the Hispanic Community Act of 2019 H.R. 7078: Evaluating Disparities and Outcomes of Telehealth During the COVID-19 Emergency Act S. 4182: Emergency Support for Nursing Homes and Elder Justice Reform Act of 2020 S. 2661 HR 4194: National Suicide Hotline Designation Act H.R. 4564: Suicide Prevention Lifeline Improvement Act S. 1737, H.R. 3165: Mental Health Parity Compliance Act H.R. 7539: Strengthening Behavioral Health Parity Act H.R. 7159, S 4282: Crisis Care Improvement and Suicide Prevention Act
Client expense: $216,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Science Foundation (NSF), SENATE
2020 · fourth_quarter · Health Issues
Title VIII Nursing Workforce Development Programs PPE, telehealth, mental health, and other resources and services to Support Nursing Education, Practice, and the Workforce in combating COVID-19 Safety and health of nurse educators and nursing students H.R. 7945/ S. 4396 - Future Advancement of Academic Nursing (FAAN) Act S.3067/H.R. 5172 - Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. S. 3634/H.R. 6650 - Health Heroes 2020 Act S. 4055 - Strengthening Americas Health Care Readiness Act H.R. 7308 - Research Investment to Spark the Economy (RISE) Act H.R. 5575 - The Primary and Behavioral Health Care Access Act H.R. 6164 / S. 3424- Perinatal Workforce Act of 2020 H.R. 3849 - Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2019 H.R.6142/S.3424 - Black Maternal Health Momnibus Act of 2020 H.R. 4974/S. 4640 - Medication Access and Training Expansion (MATE) Act 2019 H.R. 2482/ S. 2074 - Mainstreaming Addiction Treatment (MAT) Act H.R. 8061 - Community Immunity During COVID-19 Act H.R. 925 - The Heroes Act H.R. 6800 - The Heroes Act S.178 - Delivering Immediate Relief to Americas Families, Schools and Small Business Act H.R. 6561 / S. 4440 - Improving Social Determinants of Health Act of 2020 H.R. 133 - Consolidated Appropriations Act, 2021 Emergency Coronavirus Relief Act of 2020 Nursing Workforce and Research COVID-19 Limited Liability Protections Strengthening public health infrastructure Continuation of the Public Health Emergency Declaration to provide continued regulatory relief Medicare Program; Physician Fee Schedule Executive Order # 13950 Combating Race and Sex Stereotyping Section 5 of Executive Order #13890 on Protecting and Improving Medicare for Our Nations Seniors
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), SENATE, White House Office
2020 · fourth_quarter · Health Issues
Personal protective equipment for health care workers Rural Provider Access Provider Non-Discrimination Medicare Contractor Reform Medication Assisted Treatment (MAT) Scope of Practice and Supervision Requirements Pain management and non-opioid alternatives H.R.5172/S.3067 - NOPAIN Act Surprise medical billing
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; Merit-Based Incentive Payment System (MIPS) quality measures; H.R. 5172, NOPAIN Act; S. 3067, Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · third_quarter · Health Issues
H.R. 6800, The Heroes Act S. 3067, Non-Opioids Prevent Addiction In the Nation Act H.R. 5172, NOPAIN Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · third_quarter · Health Issues
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medicare/Medicaid
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. H.R. 5172, NOPAIN Act, all provisions. S. 3067, Non-Opioids Prevent Addiction In the Nation Act, all provisions.
Client expense: Not reported · Firm income: $22,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
S. 4421, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 5172, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, all provisions S. 3067, Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act\, all provisions H.R. 1503, Orange Book Transparency Act of 2019, all provisions H.R. 1520, Purple Book Continuity Act of 2019, all provisions H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, all provisions H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, all provisions H.R. 3502, Protecting People From Surprise Medical Bills Act, all provisions S. 1895, Lower Health Care Costs Act, provisions related to surprise billing H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, all provisions H.R. 3630, No Surprises Act, all provisions S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions S. 4666, A bill to establish the Commission on the Coronavirus Pandemic in the United States, all provisions S. 44507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies (GET CARE) Act of 2020, all provisions H.R. 8441, To establish certain protections and benefits for front line workers, and for other purposes, all provisions H.R. 925, The Heroes Act, provisions related to COVID-19 H.R. 6644, Health Care at Home Act of 2020, all provisions S. 3741, Health Care at Home Act of 2020, all provisions S. 3749, Public Health Emergency Privacy Act, all provisions S. 3861, Exposure Notification Privacy Act, all provisions H.R. 6585, Equitable Data Collection and Disclosure on COVID-19 Act, all provisions H.R. 7510, Assimilating Health and Equity Assessments into Decision-making (AHEAD) Act of 2020, all provisions H.R. 7255, Coronavirus Health Care Worker Wellness Act of 2020, all provisions H.R. 8094, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 4349, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 4995, Maternal Health Quality Improvement Act of 2020, all provisions H.R. 7120, George Floyd Justice in Policing Act of 2020, all provisions H.R. 2279, Safe Step Act, all provisions S. 4055, Strengthening America's Health Care Readiness Act, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions Essential Workforce Parity Act Affordable Care Act (ACA) stabilization Georgia's ACA Section 1332 waiver Public Health Emergency Fund/physician financial assistance/healthcare workforce support 21st Century Cures Act/health data and privacy Surprise medical billing Expanded Personal Protective Equipment (PPE)/clearinghouses Health equity Maternal mortality Marginalized and minoritized communities/COVID-19 disproportionate impact COVID-19/serology testing supply chain COVID-19/response strategy COVID-19/social distancing COVID-19/data collection COVID-19/ PPE/federal funding COVID-19/Vaccines COVID-19/pediatric vaccines/pharmacists and pharmacy interns COVID-19/Coding Pharmacists and COVID-19 testing Mental health parity 42 CFR Part 2, HIPAA Funding for pandemic planning and preparedness Physician burnout/suicide Telehealth waivers Augmented Intelligence (AI) Drug pricing/Executive Orders Health Quality Roadmap Datablocking Health breach notification rule Electronic health record (EHR) certification
Client expense: $4,260,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Natl Institutes of Health (NIH), Office of Natl Drug Control Policy (NDCP), President of the U.S., SENATE, State, Dept of (DOS), U.S. Immigration & Customs Enforcement (ICE), Veterans Affairs, Dept of (VA), White House Office
2020 · third_quarter · Medical/Disease Research/Clinical Labs
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, medical device technology related to the opioid epidemic and the COVID-19 pandemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Client expense: $240,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Navy, Dept of, SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2020 · third_quarter · Medicare/Medicaid
Increase access to acupuncture as an alternative pain-management option to opioids. H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Increase access to acupuncture as an alternative pain-management option to help combat opioid abuse. H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for certified acupuncturists H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Monitored issues related to prescription drug prices; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives; issues related to outpatient reimbursement.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medical/Disease Research/Clinical Labs
Medical device technology related to the opioid epidemic and the COVID-19 pandemic. H.R.5172/S.3067, NOPAIN Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Personal protective equipment for health care workers Rural Provider Access Provider Non-Discrimination Medicare Contractor Reform Medication Assisted Treatment (MAT) Scope of Practice and Supervision Requirements Pain management and non-opioid alternatives H.R.5172/S.3067 - NOPAIN Act
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues related to medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. H.R. 5172, NOPAIN Act. S. 3067, Non-Opioids Prevent Addiction In the Nation Act.
Client expense: Not reported · Firm income: Not reported
2020 · second_quarter · Health Issues
H.R. 6800, HEROES Act S. 3067, Non-Opioids Prevent Addiction In the Nation Act H.R. 5172, NOPAIN Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · second_quarter · Medicare/Medicaid
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; Merit-Based Incentive Payment System (MIPS) quality measures; H.R. 5172, NOPAIN Act; S. 3067, Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · second_quarter · Health Issues
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (Public Law 116-136)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Medicare/Medicaid
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Increase access to acupuncture as an alternative pain-management option to opioids. Lobbied: H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Increase access to acupuncture as an alternative pain-management option to help combat opioid abuse. Lobbied: H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for certified acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medical/Disease Research/Clinical Labs
Medical device technology related to the opioid epidemic; H.R.5172/S.3067, NOPAIN Act.
Client expense: Not reported · Firm income: $40,000
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medical/Disease Research/Clinical Labs
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, and medical device technology related to the opioid epidemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Client expense: $270,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Navy, Dept of, SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2020 · second_quarter · Medicare/Medicaid
Monitored issues related to prescription drug prices; H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives; issues related to outpatient reimbursement.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Health Issues
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (Public Law 116-136)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Medicare/Medicaid
Issue related to Medicare reimbursement for opioid alternative treatments, including the NOPAIN Act, HR 5172/S 3067
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medical/Disease Research/Clinical Labs
Medical device technology related to the opioid epidemic; H.R.5172/S.3067, NOPAIN Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Advocate for increased access to acupuncture as an alternative pain-management option to opioids. Lobbied: H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for certified acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Advocate for increased access to acupuncture as an alternative pain-management option to help combat opioid abuse. Lobbied: H.R. 1182/S. 2914, Acupuncture for Our Heroes Act H.R. 1183, Acupuncture for Heroes and Seniors Act Legislative efforts to gain Medicare recognition for certified acupuncturists Supported: H.R. 5172/S. 3067, the Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medical/Disease Research/Clinical Labs
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, and medical device technology related to the opioid epidemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Client expense: $330,000 · Firm income: Not reported
Government targets: Army, Dept of (Other), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Navy, Dept of, Office of Policy Development, SENATE, Transportation Security Administration (TSA), U.S. Customs & Border Protection
2020 · first_quarter · Medicare/Medicaid
Monitored issues related to prescription drug prices; issues related to the Merit-Based Incentive Payment System (MIPS); H.R. 5172, NOPAIN Act and S. 3067, Non-Opioids Prevent Addiction In the Nation Act and issues involving access to patients to non-opioid alternatives.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Medicare/Medicaid
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; Merit-Based Incentive Payment System (MIPS) quality measures; H.R. 5172, NOPAIN Act; S. 3067, Non-Opioids Prevent Addiction In the Nation Act
Client expense: Not reported · Firm income: $80,000
Government targets: SENATE
2020 · first_quarter · Health Issues
* Legislation related to the reduction of opioid use and related addictions * Implementation of HR 6, SUPPORT for Patients and Communities Act S 3067/HR 5172 Non-Opioid Prevention Addiction in the Nation Act
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (Isakson) - regulations re nonprescription drugs that are marketed without an approved new drug application S. 3052, United States-Mexico-Canada Agreement Implementation Act (Grassley) - drug pricing S. 3067, Non-Opioids Prevent Addiction In the Nation Act (Capito) - non-opioid treatments S. 3092, Expanding Access to Low-Cost Generics Act of 2019 (Smith) - exclusivity period H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.R. 4640, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 (DeFazio) - direct negotiation H.R. 4712, Fairness in Orphan Drug Exclusivity Act (Dean) - limitations on exclusive approval of orphan drugs H.R. 4810, Opioid Prescription Verification Act of 2019 (David) - dispensing of controlled substances H.R. 4906, Insulin Price Reduction Act (Diana DeGette) - insulin costs H.R. 5304, PBM Transparency in Prescription Drug Costs Act (Schrader) - PBMs H.R. 5364, End Price Gouging for Insulin Act (Beatty) - annual reference price for insulin products H.R. 5430, United States-Mexico-Canada Agreement Implementation Act (Hoyer) - drug pricing H.R. 5442, Lowest Price for Patients Act (Porter) - pharmacies to disclose any differential between the cost of a prescription drug H.R. 5444, Lower Insulin Costs Now Act (Underwood) - lowering insulin costs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office